Losartan vs Amlodipine

Both losartan and amlodipine are effective antihypertensive agents. Amlodipine (5-10 mg daily) typically reduces systolic blood pressure by 10-15 mmHg, while losartan (50-100 mg daily) produces reductions of approximately 8-12 mmHg ^[1][2][3]. In direct comparisons, amlodipine tends to produce slightly greater blood pressure reduction as monotherapy, particularly at higher doses ^[3][5].

The ALLHAT trial demonstrated that amlodipine was comparable to chlorthalidone (thiazide diuretic) for the primary endpoint of coronary heart disease events and provided excellent blood pressure control across all demographic subgroups ^[5]. Notably, amlodipine showed particular efficacy in Black patients and elderly patients — populations where the renin-angiotensin system is less activated and ARBs/ACE inhibitors may be less effective as monotherapy ^[5][7].

Losartan has important efficacy advantages in specific clinical scenarios. The LIFE trial (Losartan Intervention For Endpoint Reduction) demonstrated that losartan was superior to atenolol for preventing stroke in hypertensive patients with left ventricular hypertrophy, with a 25% relative risk reduction (p=0.001) ^[6]. Losartan is also unique among ARBs in having a modest uricosuric effect (lowering uric acid levels), which may benefit patients with comorbid gout ^[1][8].

For diabetic nephropathy, losartan has landmark evidence from the RENAAL trial showing it reduced the progression to end-stage renal disease by 28% compared to placebo (on background therapy) in patients with type 2 diabetes and nephropathy ^[4]. This renoprotective effect, mediated by reducing intraglomerular pressure through efferent arteriolar dilation, is a class effect of ARBs and ACE inhibitors that CCBs do not share ^[4][7]. Current guidelines recommend ARBs or ACE inhibitors as first-line in hypertensive patients with diabetic kidney disease or significant proteinuria ^[7].

Amlodipine is safe in heart failure patients (as demonstrated in the PRAISE trial) but does not improve heart failure outcomes ^[2]. Losartan (and the ARB class generally) has evidence for heart failure benefit, though other ARBs (valsartan, candesartan) have stronger heart failure data than losartan specifically ^[7].

The side effect profiles of losartan and amlodipine differ substantially, and these differences often drive the initial drug selection ^[1][2].

Amlodipine's most prominent side effect is dose-dependent peripheral edema, occurring in approximately 1-3% at 5 mg and 10-15% at 10 mg ^[2][3]. This edema results from arteriolar vasodilation causing increased capillary pressure and is not responsive to diuretics. Combining an ARB (like losartan) with amlodipine actually reduces this edema because ARBs promote venodilation, reducing the arteriolar-venular pressure gradient ^[3][7]. Other common side effects include headache (7%), dizziness (3%), flushing (2-3%), and fatigue (4%) ^[2]. Importantly, amlodipine does not cause metabolic side effects — it does not affect glucose, lipids, potassium, or uric acid levels ^[2][3].

Losartan is one of the best-tolerated antihypertensive medications, with a side effect profile close to placebo in clinical trials ^[1][3]. The most common complaints include dizziness (3%), upper respiratory infection (8%), and back pain (2%) ^[1]. Unlike ACE inhibitors, losartan does not cause dry cough (a common reason patients switch from ACE inhibitors to ARBs) or angioedema (though rare cases have been reported) ^[1][3]. Losartan can cause hyperkalemia, particularly in patients with renal impairment, diabetes, or those taking other potassium-elevating medications ^[1][4].

Losartan (and all ARBs/ACE inhibitors) is contraindicated in pregnancy due to fetotoxicity — it can cause renal agenesis, oligohydramnios, and fetal death, particularly in the second and third trimesters ^[1][9]. Amlodipine is not FDA-approved for use in pregnancy either, though dihydropyridine CCBs (particularly nifedipine) are commonly used for gestational hypertension ^[9]. Both drugs are associated with rare cases of angioedema, though this is more common with ACE inhibitors than with either of these medications ^[1][2].

Both medications are available as inexpensive generics. Generic losartan (25, 50, 100 mg tablets) typically costs $4-$12 per month ^[10]. Generic amlodipine (2.5, 5, 10 mg tablets) is similarly priced at $4-$10 per month and is widely available on $4 generic lists ^[10].

Losartan-hydrochlorothiazide combination (Hyzaar generic) costs $8-$20 per month, and amlodipine-benazepril (Lotrel generic) costs $10-$25 per month for patients needing combination therapy ^[10]. A fixed-dose losartan-amlodipine combination is available in some markets.

Both drugs are universally covered by insurance plans at preferred generic copay tiers. Brand-name versions (Cozaar approximately $200-$300/month; Norvasc approximately $100-$200/month) are rarely dispensed. Cost is not a distinguishing factor between these two medications for most patients.

Both medications are taken orally once daily, making them equally convenient for routine use ^[1][2]. Amlodipine has a slight pharmacokinetic advantage with its extremely long half-life (30-50 hours), providing very consistent blood pressure control and significant forgiveness for missed doses ^[2]. Losartan has a shorter half-life (6-9 hours, with its active metabolite EXP 3174 lasting 6-9 hours), but once-daily dosing is effective for 24-hour blood pressure control in most patients, though some clinicians prescribe it twice daily for better 24-hour coverage ^[1][3].

Both can be taken with or without food, morning or evening. Neither requires routine blood monitoring specifically for the drug, though losartan necessitates periodic potassium and renal function checks (particularly in patients with diabetes or renal impairment) ^[1][4]. Amlodipine does not require any laboratory monitoring beyond standard blood pressure assessment ^[2].

Neither drug requires dose tapering upon discontinuation — both can be stopped without risk of rebound phenomena, unlike some antihypertensives such as beta-blockers or clonidine ^[1][2]. Both are available in multiple tablet strengths for easy dose adjustment ^[1][2].

The choice between losartan and amlodipine depends on the patient's individual characteristics, comorbidities, and treatment goals ^[5][7].

Losartan (or another ARB/ACE inhibitor) is the preferred first-line choice for hypertensive patients with diabetes (particularly those with diabetic nephropathy or proteinuria), chronic kidney disease, heart failure, or a history of ACE inhibitor-induced cough ^[1][4][7]. The renoprotective benefits of angiotensin system blockade make losartan particularly valuable when kidney preservation is a treatment priority ^[4][6]. Losartan's uricosuric effect provides a minor additional benefit for patients with hyperuricemia or gout ^[1][8].

Amlodipine is generally preferred for Black patients and elderly patients with isolated systolic hypertension, where CCBs have demonstrated superior outcomes in large trials ^[5][7]. It is also an excellent choice for patients with stable angina (providing anti-anginal as well as antihypertensive benefits), Raynaud's phenomenon, or those who cannot tolerate the hyperkalemia risk associated with ARBs ^[2][3]. Patients with a history of significant peripheral edema may prefer losartan, as edema is uncommon with ARBs.

For many patients with uncontrolled hypertension on monotherapy, the answer is not "one or the other" but both. The combination of an ARB and a CCB is pharmacologically rational, clinically effective, and well-tolerated — it produces additive blood pressure lowering through complementary mechanisms and the ARB component actually reduces the peripheral edema that amlodipine can cause ^[3][7]. Guidelines recommend combination therapy for patients who do not reach blood pressure goals on monotherapy, and ARB + CCB is one of the preferred two-drug combinations ^[7].

Discuss your specific cardiovascular risk factors, kidney function, and medication preferences with your healthcare provider to determine the best initial therapy or combination strategy for your blood pressure management.